Jay Clemens
SRI International has received a $40 million contract to develop new contraceptive products for the Eunice Kennedy Shriver Institute of Child Health and Human Development.
SRI Biosciences will perform the preclinical development and testing of potential therapeutic products in compliance with Investigational New Drug requirements, SRI said Tuesday.
“We are pleased to continue supporting this important research on behalf of NICHD, which requires both state-of-the-art facilities and a broad range of preclinical research capabilities,” said Toufan Parman, director of general toxicology at SRI Biosciences and principal investigator for the NICHD contract.
NICHD administers laboratory research, clinical trials and epidemiological studies.
